First author of the article - Riten Kumar/LinkedIn
Jan 10, 2026, 14:40
Last day at ASH25 from Riten Kumar
Riten Kumar, Director of Thrombosis and Anticoagulation at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, shared on LinkedIn:
”Last day at ASH25 – interesting subgroup analysis from the RENOVE trial, increased CRNM bleeding with apixaban and aspirin, but not NSAIDs and Sriveda Boyala Kuntla’s excellent presentation on infection associated thrombosis, finished off with trainees – past, present and future!”
All from ASH25 featured in Hemostasis Today.
-
Sep 5, 2026, 19:20Yubrine Moraa Gachemba: BETULA Adds New Evidence for Catheter-Directed Thrombolysis in PE
-
Sep 5, 2026, 19:18John R. Mehall: The Importance of Anticoagulation Management in ECMO
-
Sep 5, 2026, 19:16Thirunavukkarasu Angappan: Why Hemophilia B Still Needs Both Plasma-Derived and Recombinant Factor IX
-
Sep 5, 2026, 19:15Michelle Leona Cecil: Comprehensive Hemophilia Care Doesn’t Begin and End With One Appointment
-
Sep 5, 2026, 19:13Amparo Santamaria: Stem Cells and Hematology – Unlocking a New Frontier in Ovarian Regeneration
-
Sep 5, 2026, 19:10Strengthening the Public Health System for Blood Disorders – Hemophilia Federation of America
-
Sep 5, 2026, 19:08Deidra D. Harris: Supporting Hemophilia of Georgia and the Bleeding Disorders Community
-
Sep 5, 2026, 19:06Katherine Blackwell: Blessed to Have the Opportunity to Speak at the Hemophilia of Indiana Annual Meeting
-
Sep 5, 2026, 19:04Christy V.: What You Need to Know about GI Bleeding and Hemophilia